RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
Status:
Unknown status
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
This study evaluates efficacy and safety of rilpivirine as substitutive agent for the
nucleosidic backbone of HAART in virologic suppressed patients when combined with
cobicistat-boosted darunavir.